# Amantadine and Transcranial Magnetic Stimulation for Treating Fatigue in Multiple Sclerosis

> **NCT05809414** · PHASE3 · UNKNOWN · sponsor: **Hospital San Carlos, Madrid** · enrollment: 144 (estimated)

## Conditions studied

- Multiple Sclerosis
- Fatigue

## Interventions

- **DEVICE:** Transcranial Magnetic Stimulation
- **DRUG:** Amantadine Hydrochloride 100 mg (milligrams) Oral Capsule

## Key facts

- **NCT ID:** NCT05809414
- **Lead sponsor:** Hospital San Carlos, Madrid
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-28
- **Primary completion:** 2024-07-15
- **Final completion:** 2025-02-28
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2023-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05809414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05809414, "Amantadine and Transcranial Magnetic Stimulation for Treating Fatigue in Multiple Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05809414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*